as on December 30, 2025 at 2:29 am IST
Day's Low
Day's High
3.18%
Downside
7.62%
Upside
52 Week's Low
52 Week's High
63.12%
Downside
7.93%
Upside
Check Merus Nv market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$-
EPS (TTM)
0Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
0EBITDA
-
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
0.00%
Compare market cap, revenue, PE, and other key metrics of Merus Nv with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $- | NA | NA | 0.00% | |
| BUY | $33.3B | 271.93% | -16.34 | -264.83% | |
| BUY | $48.9B | 107.67% | 1233.33 | 1.36% | |
| BUY | $119.8B | 97.15% | 32.89 | 31.35% | |
| BUY | $80.1B | 40.12% | 18.12 | 32.13% |
Based on 20 analysts
95.00%
Buy
5.00%
Hold
0.00%
Sell
Based on 20 analysts, 95% of analysts recommend a 'BUY' rating for Merus Nv. Average target price of $97
Get share price movements and forecasts by analysts on Merus Nv.
What analysts predicted
7.22%UPSIDE
Target Price
$97
Current Price
$90
Analyzed by
20 Analysts
Target
$97.00
Merus Nv target price $97, a slight upside of 7.22% compared to current price of $90. According to 20 analysts rating.
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 29 September
Mon, 05:02 PM
-Genmab expects to finalize the Merus acquisition in Q1 2026, enhancing its drug pipeline.
Mon, 07:16 PM
-Citi downgraded Merus to Neutral after Genmab's acquisition announcement, with a price target of $97.
Mon, 07:45 PM
-Genmab's acquisition of Merus valued at $97 per share, a 41% premium over previous closing price.
Today's Timeline - 29 September
Mon, 09:18 PM
-Merus shares surged 36% after Genmab agreed to acquire the company for $8 billion, or $97 per share.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
![]()
Netprofit is up for the last 2 quarters, -134.32M → -81.55M (in $), with an average increase of 64.7% per quarter
Revenue Rich
![]()
Revenue is up for the last 2 quarters, 7.49M → 10.37M (in $), with an average increase of 27.8% per quarter
Against Peers
![]()
In the last 1 year, Insmed Incorporated has given 155.4% return, outperforming this stock by 41.4%
Against Peers
![]()
In the last 3 years, Insmed Incorporated has given 782.6% return, outperforming this stock by 300.8%
Price Dip
![]()
In the last 7 days, MRUS stock has moved down by -7.1%
| Organisation | Merus Nv |
| E-voting on shares | Click here to vote |
Merus Nv share price today is $90 as on at the close of the market. Merus Nv share today touched a day high of $96.86 and a low of $87.14.
Merus Nv share touched a 52 week high of $97.14 on and a 52 week low of $33.19 on . Merus Nv stock price today i.e. is closed at $90,which is 7.35% down from its 52 week high and 171.17% up from its 52 week low.
Indian investors can start investing in Merus Nv (MRUS) shares with as little as ₹91.862 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹918.62 in Merus Nv stock (as per the Rupee-Dollar exchange rate as on ).
Based on Merus Nv share’s latest price of $90 as on December 30, 2025 at 2:29 am IST, you will get 0.1111 shares of Merus Nv. Learn more about
fractional shares .